Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of any of the following hematologic malignancies: * Acute myeloid leukemia (AML) meeting any of the following criteria: * First complete remission with high-risk karyotype * Translocations t(15;17) allowed only if failed first-line induction therapy OR molecular evidence of persistent disease exists * Translocations t(8;21) and inv(16) allowed only if failed first-line induction therapy * Second or subsequent complete remission * Minimal residual disease\* * Acute lymphoblastic leukemia meeting any of the following criteria: * Failed induction therapy and has minimal residual disease\* by salvage therapy * First complete remission with high-risk karyotype (e.g., t\[4;11\] or t\[9;22\]) * Relapsed disease allowed provided a second or subsequent complete remission or minimal residual disease\* is achieved * Chronic myelogenous leukemia meeting any of the following criteria: * Persistent or relapsed disease after 1 year of imatinib mesylate therapy * Accelerated phase or blast crisis * Blast crisis allowed after reinduction chemotherapy places disease in chronic phase * Myelodysplastic syndromes meeting any of the following criteria: * Refractory to medical management * Cytogenetic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to AML (e.g., refractory anemia…